Soon after the EXCEL “Scandal” the NOBLE 5-year Outcomes Come Out: Mere Coincidence?

There is no such thing as coincidence, at least not for the evidence-based medical science. This is what the NOBLE 5-year outcomes, soon to be published in the Lancet, seem to say, in line with the BBC exposé of the EXCEL study.

The NOBLE study randomized patients with left main disease to compare PCI vs CABG.

With a non-inferiority design and carried out in 36 centers across 9 European countries, had the combined end point of major cardiac and cerebrovascular events (MACCE), which include all cause death, non-procedural myocardial infarction, repeat revascularization and stroke. Each one of these points separately were secondary end points. 


Read also: Latest Guidelines “Dropped” After Scandal Over EXCEL Results.


Between 2008 and 2015, 1201 patients were included, 598 undergoing PCI and 603 CABG. 17 patients were lost at follow up and the study was left with 592 patients in each group.

The predefined number of events for sufficient statistical power to assess the primary end point was reached at mean 4.9 years. 

The Kaplan-Meier curves at 5 years showed 28% MACCE rate for PCI and 19% for CABG (HR=1.58; CI 95% 1.24 to 2.01) which exceeds the non-inferiority limit.


Read also: The EXCEL Authors’ Answer to the BBC Investigation.


CABG resulted superior to PCI for the combined primary end point (p=0.0002).

All-cause mortality resulted identical between both strategies (9% for both, p=0.68), but there was a difference in infarction (8% for PCI vs 3% for CABG; p=0.0002) and repeat revascularization rates (17% for PCI vs. 10% for CABG; p=0.0009).

Conclusion

In patients with left main disease, PCI was associated with worse clinical outcomes at 5 years vs. CABG. Mortality resulted similar between both strategies, but PCI presented more spontaneous infarctions and more repeat revascularization.

Original Title: Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.

Reference: Niels R Holm et al. Lancet 2019 Dec 23. Online before print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....